Suppr超能文献

一种强大的非小细胞肺癌生物标志物——miR-7-5p:其验证及基于表面等离子体共振的检测潜在探针

A Robust NSCLC Biomarker- miR-7-5p: Its Validation and Potential SPR-Based Probe for Detection.

作者信息

Dhara Chandrajeet, Dhara Anindita, Gantayat Saumyatika

机构信息

School of Biosciences, Apeejay Stya University Gurugram, Sohna-Palwal Road, Haryana-122103, India.

Institute for Pharmacology and Toxicology, Universitatklinikum Carl Gustav Carus, TU Dresden, Germany.

出版信息

Microrna. 2025;14(2):112-123. doi: 10.2174/0122115366325862241031071038.

Abstract

MicroRNA abundance as a particular biomarker for precisely identifying cancer metastases has emerged in recent years. The expression levels of miRNA are analyzed to get insights into cancer tissue detection and subtypes. Similar to other cancer types, the miRNA shows high levels of target mRNA dysregulation in association with non-small cell lung carcinoma (NSCLC). Among many promising cancer biomarkers for NSCLC, miR-7-5p has shown significant downregulation in the NSCLC tissues and targets proto-oncogenes like PAK2 and NOVA2. The expression levels of different proto-oncogenes targeting the miR-7-5p in NSCLC showed that the EGFR-mutated NSCLC has an experimental validation. The target validation of the miR-7-5p could be analyzed using SPR (Surface plasmon resonance) based sensors at a single nanoparticle level, such as Au nanocube, due to its high specificity and accountability. Despite being an accountable tool for cancer diagnosis, miRNA-based biomarkers sometimes cause poor diagnostic specificity and reproducibility due to their heterogenicity and immunogenicity in cancer detection. To overcome these shortcomings, the biomarkers need to be validated according to recent clinical studies.

摘要

近年来,微小RNA丰度作为一种精确识别癌症转移的特定生物标志物已逐渐出现。分析微小RNA的表达水平有助于深入了解癌症组织检测和亚型。与其他癌症类型类似,微小RNA在非小细胞肺癌(NSCLC)中显示出与靶mRNA高度失调相关。在众多有前景的NSCLC癌症生物标志物中,miR-7-5p在NSCLC组织中显著下调,并靶向PAK2和NOVA2等原癌基因。在NSCLC中靶向miR-7-5p的不同原癌基因的表达水平表明,EGFR突变的NSCLC具有实验验证。由于其高特异性和可问责性,miR-7-5p的靶标验证可以在单个纳米颗粒水平上使用基于表面等离子体共振(SPR)的传感器进行分析,例如金纳米立方体。尽管基于微小RNA的生物标志物是癌症诊断的可靠工具,但由于它们在癌症检测中的异质性和免疫原性,有时会导致诊断特异性和可重复性较差。为了克服这些缺点,需要根据最近的临床研究对生物标志物进行验证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验